Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.

ABSTRACT: Ejection fraction (EF) is a key component of heart failure (HF) classification. However, the biologic basis of HF with mildly reduced EF (HFmrEF) as a distinct biologic entity distinct from HF with preserved EF (HFpEF) and reduced EF (HFrEF) has not been well characterized. The EXSCEL trial randomized participants with type 2 diabetes (T2DM) to a once-weekly glucagon-like peptide receptor agonist (GLP-1 RA) exenatide (EQW) vs. placebo. For this study, profiling of ~ 5000 proteins using the SomaLogic SomaScan platform was performed in baseline and 12-month serum samples from N = 1199 participants with prevalent HF at baseline. Unsupervised principal component analysis (PCA) and ANOVA (FDR p < 0.1) were used to identify proteins that were significantly between three EF groups (EF > 55% [HFpE

SUBMITTER: Peters AE 

PROVIDER: S-EPMC12361379 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature